Bats are a unique group of mammals of the order Chiroptera. They are highly diversified and are the group of mammals with the second largest number of species. Such highly diversified cell types and receptors facilitate them to be potential hosts of a large variety of viruses. Bats are the only group of mammals capable of sustained flight, which enables them to disseminate the viruses they harbor and enhance the chance of interspecies transmission. This article aims at reviewing the various aspects of the global epidemiology of bat coronaviruses (CoVs). Before the SARS epidemic, bats were not known to be hosts for CoVs. In the last 15 years, bats have been found to be hosts of >30 CoVs with complete genomes sequenced, and many more if those without genome sequences are included. Among the four CoV genera, only alphaCoVs and betaCoVs have been found in bats. As a whole, both alphaCoVs and betaCoVs have been detected from bats in Asia, Europe, Africa, North and South America and Australasia; but alphaCoVs seem to be more widespread than betaCoVs, and their detection rate is also higher. For betaCoVs, only those from subgenera Sarbecovirus, Merbecovirus, Nobecovirus and Hibecovirus have been detected in bats. Most notably, horseshoe bats are the reservoir of SARS-CoV, and several betaCoVs from subgenus Merbecovirus are closely related to MERS-CoV. In addition to the interactions among various bat species themselves, bat–animal and bat–human interactions, such as the presence of live bats in wildlife wet markets and restaurants in Southern China, are important for interspecies transmission of CoVs and may lead to devastating global outbreaks.

S eventeen years after the severe acute respiratory syndrome (SARS) epidemic, an outbreak of pneumonia, now called coronavirus disease (COVID-19), was reported in Wuhan, China. Some of the early casepatients had a history of visiting the Huanan Seafood Wholesale Market, where wildlife mammals are sold, suggesting a zoonotic origin. The causative agent was rapidly isolated from patients and identified to be a coronavirus, now designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (1). SARS-CoV-2 has spread rapidly to other places; 113,702 cases and 4,012 deaths had been reported in 110 countries/areas as of March 10, 2020 (2). In Hong Kong, 130 cases and 3 deaths had been reported. SARS-CoV-2 is a member of subgenus Sarbecovirus (previously lineage b) in the family Coronaviridae, genus Betacoronavirus, and is closely related to SARS-CoV, which caused the SARS epidemic during 2003, and to SARS-related-CoVs (SARSr-CoVs) in horseshoe bats discovered in Hong Kong and mainland China (3-5). Whereas SARS-CoV and Middle East respiratory syndrome coronavirus were rapidly traced to their immediate animal sources (civet and dromedaries, respectively), the origin of SARS-CoV-2 remains obscure. SARS-CoV-2 showed high genome sequence identities (87.6%-87.8%) to SARSr-Rp-BatCoV-ZXC21/ ZC45, detected in Rhinolophus pusillus bats from Zhoushan, China, during 2015 (6). A closer-related strain, SARSr-Ra-BatCoV-RaTG13 (96.1% genome identity with SARS-CoV-2), was recently reported in Rhinolophus affinis bats captured in Pu'er, China, during 2013 (7). Subsequently, Pangolin-SARSr-CoV/ P4L/Guangxi/2017 (85.3% genome identity to SARS-CoV-2) and related viruses were also detected in smuggled pangolins captured in Nanning, China, during 2017 (8) and Guangzhou, China, during 2019 (9). To elucidate the evolutionary origin and pathway of SARS-CoV-2, we performed an in-depth genomic, phylogenetic, and recombination analysis in relation to SARSr-CoVs from humans, civets, bats, and pangolins (10). The Study We downloaded 4 SARS-CoV-2, 16 human/civet-SARSr-CoV, 63 bat-SARSr-CoV and 2 pangolin-SARSr-CoV genomes from GenBank and GISAID (https:// www.gisaid.org). We also sequenced the complete genome of SARS-CoV-2 strain HK20 (GenBank accession no. MT186683) from a patient with COVID-19 in Hong Kong. We performed genome, phylogenetic, and recombination analysis as described (11). The 5 SARS-CoV-2 genomes had overall 99.8%-100% nt identities with each other. These genomes showed 96.1% genome identities with SARSr-Ra-BatCoV-RaTG13, 87.8% with SARSr-Rp-BatCoV-ZC45, 87.6% with SARSr-Rp-BatCoV-ZXC21, 85.3% with pangolin-SARSr-CoV/P4L/Guangxi/2017, and 73.8%-78.6% with other SARSr-CoVs, including human/civet-SARSr-CoVs (Table 1, https://wwwnc. cdc.gov/EID/article/26/7/20-0092-T1.htm). Most predicted proteins of SARS-CoV-2 showed high amino acid sequence identities with that of SARSr-Ra-BatCoV RaTG13, except the receptor-binding

Although bats are known to harbor Middle East Respiratory Syndrome coronavirus (MERS-CoV)-related viruses, the role of bats in the evolutionary origin and pathway remains obscure. We identified a novel MERS-CoV-related betacoronavirus, Hp-BatCoV HKU25, from Chinese pipistrelle bats. Although it is closely related to MERS-CoV in most genome regions, its spike protein occupies a phylogenetic position between that of Ty-BatCoV HKU4 and Pi-BatCoV HKU5. Because Ty-BatCoV HKU4 but not Pi-BatCoV HKU5 can use the MERS-CoV receptor human dipeptidyl peptidase 4 (hDPP4) for cell entry, we tested the ability of Hp-BatCoV HKU25 to bind and use hDPP4. The HKU25-receptor binding domain (RBD) can bind to hDPP4 protein and hDPP4-expressing cells, but it does so with lower efficiency than that of MERS-RBD. Pseudovirus assays showed that HKU25-spike can use hDPP4 for entry to hDPP4-expressing cells, although with lower efficiency than that of MERS-spike and HKU4-spike. Our findings support a bat origin of MERS-CoV and suggest that bat CoV spike proteins may have evolved in a stepwise manner for binding to hDPP4.

To control the COVID-19 pandemic and prevent its resurgence in areas preparing for a return of economic activities, a method for a rapid, simple, and inexpensive point-of-care diagnosis and mass screening is urgently needed. We developed and evaluated a one-step colorimetric reverse-transcriptional loop-mediated isothermal amplification assay (COVID-19-LAMP) for detection of SARS-CoV-2, using SARS-CoV-2 isolate and respiratory samples from patients with COVID-19 (n = 223) and other respiratory virus infections (n = 143). The assay involves simple equipment and techniques and low cost, without the need for expensive qPCR machines, and the result, indicated by color change, is easily interpreted by naked eyes. COVID-19-LAMP can detect SARS-CoV-2 RNA with detection limit of 42 copies/reaction. Of 223 respiratory samples positive for SARS-CoV-2 by qRT-PCR, 212 and 219 were positive by COVID-19-LAMP at 60 and 90 min (sensitivities of 95.07% and 98.21%) respectively, with the highest sensitivities among nasopharyngeal swabs (96.88% and 98.96%), compared to sputum/deep throat saliva samples (94.03% and 97.02%), and throat swab samples (93.33% and 98.33%). None of the 143 samples with other respiratory viruses were positive by COVID-19-LAMP, showing 100% specificity. Samples with higher viral load showed shorter detection time, some as early as 30 min. This inexpensive, highly sensitive and specific COVID-19-LAMP assay can be useful for rapid deployment as mobile diagnostic units to resource-limiting areas for point-of-care diagnosis, and for unlimited high-throughput mass screening at borders to reduce cross-regional transmission.